Prostate cancer is a global health problem, but incidence varies considerably across
different continents. Asia is traditionally considered a low-incidence area, but the incidence …

Genomic aberrations of the PTEN tumour suppressor gene are among the most common in
prostate cancer. Inactivation of PTEN by deletion or mutation is identified in∼ 20% of …

Prostate cancer rates vary substantially by race, ethnicity, and geography. These disparities
can be explained by variation in access to screening and treatment, variation in exposure to …

Background Biomarkers that are validated in independent cohorts are needed to improve
risk assessment for prostate cancer (PCa). Objective A racially diverse cohort of men (20 …

Over the past decades, consistent studies have shown that race/ethnicity have a great
impact on cancer incidence, survival, drug response, molecular pathways and epigenetics …

Ethnic and geographic differences in cancer incidence, prognosis, and treatment outcomes
can be attributed to diversity in the inherited (germline) and somatic genome. Although …

Abstract Purpose: African American (AFR) men have the highest mortality rate from prostate
cancer (PCa) compared with men of other racial/ancestral groups. Differences in the …

Prostate cancer is the most frequent nonskin cancer and second most common cause of
cancer-related deaths in man. Prostate cancer is a clinically heterogeneous disease with …

Racial disparities in prostate cancer have not been well characterized on a genomic level.
Here we show the results of a multi-institutional retrospective analysis of 1,152 patients (596 …

Background: PTEN is a tumor suppressor frequently deleted in prostate cancer that may be
a useful prognostic biomarker. However, the association of PTEN loss with lethal disease …